Taiwan Arms Sales and the US-China Trade War

The United States has long anchored its Indo‑Pacific posture on the “first island chain,” a line of allies stretching from Japan through the Philippines to Taiwan. By arming these partners, Washington keeps potential conflicts away from its mainland coast. Taiwan occupies a pivotal spot in that chain, and although there is no formal mutual‑defense treaty, the Taiwan Relations Act of 1979 and the Reagan‑era Six Assurances obligate the U.S. to supply defensive weapons and to refrain from consulting Beijing on those sales. This framework creates a deliberate strategic ambiguity about whether America would intervene directly in a Chinese invasion.

During Trump’s second term, the U.S.–China trade war reshaped that status quo. Facing Chinese rare‑earth restrictions, the administration began treating the $14 billion Taiwan arms package as a bargaining chip, openly discussing sales with Beijing at the Busan and Beijing summits. While a $11 billion deal approved in December 2025 kept overall sales on a record trajectory, the May 2026 $1 billion package was put on hold under the pretext of stock‑pile concerns. Analysts see the delay as a tactical move to extract concessions in a broader trade agreement, even as Congress watches closely.

The coming months will hinge on congressional calculations and the looming 2026 midterms. Democrats are poised to oppose any Trump‑led softening of the Six Assurances, while vulnerable Republican members risk primary challenges if they side against the president. If pressure mounts, lawmakers could codify the assurances into law, forcing future administrations to keep Taiwan arms sales insulated from trade talks. Regardless of the political tug‑of‑war, the trajectory points toward continued, possibly record‑high, U.S. weapons deliveries to Taipei. Companies with supply‑chain exposure to Chinese tariffs should monitor these developments, as shifts in defense policy often ripple through broader trade and technology markets.